다운로드 Oncology Nursing Drug Handbook - v3.5.13

Oncology Nursing Drug Handbook - v3.5.13 또는 Inject App, Pacify, Dexcom G6, iDentist Dental practice management, Patchwork, Jan Aushadhi Sugam (BPPI), 의료 카테고리에서 가장 멋진 애플리케이션 중 하나에 대해 들어 보셨습니다.

물론 모든 게임이나 애플리케이션이 모든 휴대 전화와 호환되는 것은 아닙니다. 게임이나 애플리케이션이 기기에서 사용할 수없는 경우도 있으며 시스템 버전에 따라 다릅니다. Android 운영 체제, 화면 해상도 또는 국가 Google Play에서 액세스를 허용합니다. APKPanda는 다운로드 할 수있는 Android APK 파일을 제공하며 이러한 제한을 고수하지 않습니다.>
Oncology Nursing Drug Handbook - v3.5.13 최신 버전은 3.5.13, 출시일은 2020-06-25이며 크기는 8.4 MB입니다.Skyscape Medpresso Inc에서 개발 한 Oncology Nursing Drug Handbook - v3.5.13는 Android 버전이 Android 5.0+ 이상이어야합니다. 따라서 필요한 경우 휴대 전화를 업데이트해야합니다.

약 1000 회 다운로드했습니다. 원하는 경우 Android 기기에 개별적으로 다운로드하거나 설치된 앱을 업데이트 할 수 있습니다. 앱을 업데이트하면 최신 기능에 대한 액세스 권한이 부여되고 애플리케이션 보안 및 안정성이 향상됩니다.

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity